Versant’s Cimeio debuts with $50M to shield cell therapies with gene editing

As the latest company to emerge from Versant, Cimeio has a new approach to hematopoietic stem cell transplants that could both reduce the burden of conditioning regimens and address residual disease through shielding the transplanted cells from conditioning immunotherapy.

And Cimeio Therapeutics Inc.’s longer vision for the platform stretches its applications beyond those of traditional stem cell transplants into autoimmune diseases and other indications that can be treated by reprogramming the immune system...